ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,575.90
-1.39%
S&P ASX All Technology
2,970.40
-1.25%
Brent Oil
88.165
0.00%
US Dollar vs AUD
1.53139
0.00%
Bitcoin
63,787.21
0.59%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Immutep Ltd (IMMP)

  7. Immutep Ltd (IMMP) News

IMMP

Immutep (IMMP)

Immutep Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMMP
DateTimeSourceHeadlineSymbolCompany
24/04/202422:00GlobeNewswire Inc.Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort BNASDAQ:IMMPImmutep Ltd
18/04/202422:00GlobeNewswire Inc.Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761NASDAQ:IMMPImmutep Ltd
17/04/202422:00GlobeNewswire Inc.Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
06/03/202400:00GlobeNewswire Inc.Immutep Announces First Clinical Data from 90mg Dosing of EftiNASDAQ:IMMPImmutep Ltd
31/01/202408:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
31/01/202400:00GlobeNewswire Inc.Immutep Quarterly Activities Report Q2 FY24NASDAQ:IMMPImmutep Ltd
05/01/202400:00GlobeNewswire Inc.First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial CancerNASDAQ:IMMPImmutep Ltd
22/12/202300:00GlobeNewswire Inc.Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
21/12/202322:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
08/12/202300:00GlobeNewswire Inc.Immutep Receives A$2.6 million R&D Tax Incentive from French GovernmentNASDAQ:IMMPImmutep Ltd
23/11/202300:00GlobeNewswire Inc.Immutep Announces Site Expansion for INSIGHT-003 Phase I TrialNASDAQ:IMMPImmutep Ltd
10/11/202300:00GlobeNewswire Inc.Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell CarcinomaNASDAQ:IMMPImmutep Ltd
07/11/202300:00GlobeNewswire Inc.Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast CancerNASDAQ:IMMPImmutep Ltd
04/11/202303:00GlobeNewswire Inc.Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
03/11/202321:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
02/11/202323:00GlobeNewswire Inc.Immutep to Participate in November Investor EventsNASDAQ:IMMPImmutep Ltd
31/10/202323:00GlobeNewswire Inc.Immutep Quarterly Activities Report Q1 FY24NASDAQ:IMMPImmutep Ltd
25/10/202323:00GlobeNewswire Inc.Immutep receives ~A$1.13 million R&D Tax IncentiveNASDAQ:IMMPImmutep Ltd
25/10/202321:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
24/10/202323:00GlobeNewswire Inc.Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023NASDAQ:IMMPImmutep Ltd
24/10/202321:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
23/10/202323:00GlobeNewswire Inc.Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
16/10/202323:00GlobeNewswire Inc.Immutep Announces Publication of Abstracts at ESMO Congress 2023NASDAQ:IMMPImmutep Ltd
03/10/202323:00GlobeNewswire Inc.Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNASDAQ:IMMPImmutep Ltd
21/09/202322:00GlobeNewswire Inc.Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial UseNASDAQ:IMMPImmutep Ltd
05/09/202323:00GlobeNewswire Inc.Immutep to Participate in September Investor ConferencesNASDAQ:IMMPImmutep Ltd
01/08/202322:00GlobeNewswire Inc.Immutep Receives Positive Scientific Advice from European Medicines AgencyNASDAQ:IMMPImmutep Ltd
31/07/202322:00GlobeNewswire Inc.Immutep Quarterly Activities Report Q4 FY23NASDAQ:IMMPImmutep Ltd
31/07/202322:00GlobeNewswire Inc.Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023NASDAQ:IMMPImmutep Ltd
28/07/202322:00GlobeNewswire Inc.First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue SarcomaNASDAQ:IMMPImmutep Ltd
 Showing the most relevant articles for your search:NASDAQ:IMMP

Your Recent History

FX
AUDCAD
AUD vs CAD
CCOM
SILVER
SILVER
ASX
XMM
S&P ASX 300 Metals and M...
ASX
AMP
AMP
ASX
XTO
S&P ASX 100
COIN
ETHUSD
Ethereum
ASX
XAO
Australian SE All Ordina...
ASX
XFL
S&P ASX 50
NYSE
DIS
Walt Disney
NASDAQ
GOOGL
Alphabet
ASX
NCM
Newcrest Mining
ASX
WBC
Westpac Banking
NYSE
XOM
Exxon Mobil
FX
EURAUD
Euro vs AUD
NYSE
KO
Coca Cola
FX
AUDJPY
AUD vs Yen
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved